BLT - Blis Technologies

[winner69]

Jeez …..BLT share price 2.3 cents

Suppose only consolation is that it’s been lower than this in the past

Still a $30m company …that’s good

[silverblizzard888]

Jeez …..BLT share price 2.3 cents

Suppose only consolation is that it’s been lower than this in the past

Still a $30m company …that’s good

Over the years they've proven their cost structure is too high and their products aren't selling like hotcakes even in a pandemic setting. Something needs to change, they keep doing the same thing and expecting a different result. They are too reliant on their core probiotic products.

They probably should consider selling supplement products to sell alongside their probiotics, like vitamins. I know its not their core focus, but sometimes you need to sell other products while utilizing your brand to make extra margin and profits, so you can spread out your fix cost.

[mr optimistic]

Mmmmm. If they dont know how to sell their unique products, how do you expect them to sell generic products like vitamins. It has nothing to do with their cost structure. They simply dont have the knowledge on the board or the exec team with selling FMC. End of story. It starts at the top. Their chairman might be good at running a meeting, but he doesnt know a thing about selling. And their CEO seems like a nice guy. But come on, moving milk powder for Fonterra doesnt mean you know how to sell products to consumers. I bet their replacement for the nice guy CEO is someone that worked at GSK or some other global supplier. Just watch.

[Sideshow Bob]

Mmmmm. If they dont know how to sell their unique products, how do you expect them to sell generic products like vitamins. It has nothing to do with their cost structure. They simply dont have the knowledge on the board or the exec team with selling FMC. End of story. It starts at the top. Their chairman might be good at running a meeting, but he doesnt know a thing about selling. And their CEO seems like a nice guy. But come on, moving milk powder for Fonterra doesnt mean you know how to sell products to consumers. I bet their replacement for the nice guy CEO is someone that worked at GSK or some other global supplier. Just watch.

I share your lack of optimism Mr Optimistic!

Unique products and have never been able to create a brand and generate meaningful sales.

What I would be interested in, is what happens when their patents run out??

[mr optimistic]

I think those patents are done and dusted

[silverblizzard888]

Mmmmm. If they dont know how to sell their unique products, how do you expect them to sell generic products like vitamins. It has nothing to do with their cost structure. They simply dont have the knowledge on the board or the exec team with selling FMC. End of story. It starts at the top. Their chairman might be good at running a meeting, but he doesnt know a thing about selling. And their CEO seems like a nice guy. But come on, moving milk powder for Fonterra doesnt mean you know how to sell products to consumers. I bet their replacement for the nice guy CEO is someone that worked at GSK or some other global supplier. Just watch.

For a company delivering $10 million sales its actually pretty decent, though not the best, but definitely not the worse. Now the big question would be how do you not make a lot of profit from those number of sales, its because they aren't making more profit margin to cover their cost, hence cost structure matters. I understand where you are coming from that if they were great at sales they would sell enough probiotics to cover the cost anyway, but the simple answer is they aren't so they have to explore alternative methods. The low hanging fruit would be selling other products and diversifying their cost base.

BLT have always approached this field as pioneers rather than players in a competitive field. They want a retail approach without tailoring their range to be comprehensive to their customer. When consumers buy products they generally like to stick to certain brands because they can build trust with the brand and even build a following. Think Blackmores, Nutralife and Swisse, they all think of themselves as a health company with a comprehensive range of products and when people buy one of their product they normally buy others in the same brand too. Theres a higher chance someone buying a Blackmore vitamin will be think they will buy Blackmore's probiotic more than BLT's probiotic simply because they've used their product before and build some trust.

People don't go to Mcdonalds for the burger alone, they want the whole combo of fries and drink. Not only does it serve the customer in what they want, but they've successful upsold them on extra product and made a lot more margin as a result and hence making huge profits. Imagine consumers on BLT's website ordering probiotic products and they see a daily vitamin combo, its a high margin product leveraging existing expenses. People who care deep enough about probiotics probably cares for their general health too, so the conversion would be pretty decent. Just some extra sales could be the difference between having a profitable year or not.

It also works the other way round too, someone who never though about taking probiotics decides they will take their daily vitamin product, then one day decides to explore their probiotic product and gives it a try. They simply don't have a gateway product to their probiotics and not a comprehensive range of products to build a fully fledged brand.

[Sampan]

This company needs a shakeup - the management/directors are there for the pay check, they add little in terms of industry or product value and don't have enough skin in the game. I mean, with the share price this low, I asked if anyone on management was buying shares....cue blank stares, looking shiftily to the guy next to them! It really is a joke and the share price will meander along at these levels for the foreseeable future. Its just not a company you want to have shares in

[Sideshow Bob]

https://www.nzx.com/announcements/412007

Revenue growth and a profitable second half year

Blis Technologies Limited (NZX:BLT) (Blis, the Company) has today reported its results for the 12 months to 31 March 2023. Blis has delivered revenue of $10.2 million, 14% growth on the prior year, with an EBITDA loss of $0.6 million and a net deficit of $1.4m. A positive EBITDA of $0.6m and a net profit of $0.3m was delivered in the second half of the year. These results are in line with the upgraded guidance provided in early April 2023.

Key highlights for FY23 are:

• $10.2m Trading Revenue, 14% growth
• $0.6m EBITDA Loss
• $1.4m Net deficit
• 2HY23 positive EBITDA and a Net Profit
• Business to Business revenue growth 11%
• Business to Consumer revenue growth 21%
• First royalty payments from the Probi licensing partnership

“Blis Technologies’ (Blis) financial performance continues to improve. We have seen a rebound in revenue from Europe, the first revenue from our strategic partnership with Probi and early signs of an improved performance following the strategy reset.” said Blis Chairman Geoff Plunket.

“In July 2022 we confirmed a shift in our strategy, aimed at focusing on our strengths and returning to a sustained profitable trading position. Our strengths centre around scientific discovery and probiotic innovation. We are pleased with our progress implementing the revised strategy and there are early positive signs of this delivering improved results.” added Blis CEO Brian Watson.

Key enablers of our strategy reset have been implemented. This includes quickly restructuring our people resource and roles into B2B and B2C sales channel teams, a reset of our innovation pipeline to support the B2B priorities, and the transition out of Unconditional Skincare Co. (USC) and retail sales in Canada.

Along with this we are seeing early indicators of this refocus delivering improved performance outcomes. In the second half of the financial year, we saw a positive EBITDA and profit, our B2B business grew, and we delivered growth across prioritised B2C markets.

Outlook

Good progress has been made on our key objective of returning the company to a profitable trading position. The coming year will see a continued focus on both growing revenue and enhancing research and development capabilities.

Ends

[bulyak]

haha. I think this is the same AR I read 5 years ago. What a joke.....

[bulyak]

I wasnt far off.

BLIS ACHIEVES IMPORTANT MILESTONES IN 2019 FINANCIAL YEAR

FY19 Highlights:
o $0.4m maiden net profit
o $0.9m EBITDA
o 59% growth in total revenue drives 5-year CAGR of + 45%
o Launch into the Australian pharmacy market
o Launch onto the Amazon US platform
o Key regulatory approvals:
- BLIS M18(TM) Australia TGA approval
- BLIS M18(TM) US "self-affirmed" GRAS (April 2019, US FDA "No Objection"
status)

Blis Technologies Limited (NZX:BLT) (Blis, Company) has today reported its
results for the 12 months to 31 March 2019. In line with the market guidance
provided on 1 April, the Company has delivered a maiden net profit of $0.4m
after reporting a loss of $1.0m for the prior year.

FY19 total revenue was $8.4m, an increase of 59% on the prior year. Earnings
before interest, tax, depreciation and amortisation (EBITDA ) was $0.9m, a
slight increase on guidance provided to the market in April 2019 and a
turnaround from the $0.4m loss achieved in the prior year.

"This result represents a significant turning point for the Company in line
with our goal of delivering sustainable profitable growth" said Blis Chair,
Tony Offen.